Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817041 | 1.00 | FASN (0.47) | FASNKEAP1FDFT1MAPTKDM4E | |
| SCHEMBL6069576 | 1.00 | FASN (0.47) | FASNKEAP1FDFT1MAPTKDM4E | |
| SCHEMBL6069567 | 1.00 | FASN (0.47) | FASNKEAP1FDFT1MAPTKDM4E | |
| SCHEMBL5194706 | 0.81 | TLR9 (0.46) | FASNKEAP1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5194716 | 0.81 | TLR9 (0.46) | FASNKEAP1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3684121 | 0.81 | TLR9 (0.46) | FASNKEAP1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5194710 | 0.81 | TLR9 (0.46) | FASNKEAP1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL28653386 | 0.80 | F2RL1 (0.47) | KDM4ESMN1; SMN2ALDH1A1FFAR1 | |
| SCHEMBL6069900 | 0.79 | TSHR (0.57) | MAPTSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL6069915 | 0.79 | TSHR (0.57) | MAPTSMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1196590-B1 | PROCESS OF SEPARATION OF EPOXIDE-ENANTIOMER MIXTURES BY EPOXIDE-HYDROLASE PRODUCING MICROORGANISMS | BASF SE (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-7056947-B2 | For inhibiting (cysteine) proteases/caspases; for treatment of viral infections, stroke, neurodegenerative disease, and inflammatory diseases | GEORGIA TECH RESEARCH CORP. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040048327-A1 | Aza-peptide epoxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-11 | — | — | US | disclosed |
| WO-2004005270-A1 | AZA-PEPTIDE EPOXIDES | GEORGIA TECH RESEARCH CORPORATION (US) | 2004-01-15 | — | — | WO | disclosed |
| EP-1196590-A1 | EPOXIDE HYDROLASES FROM STREPTOMYCES | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007623-A1 | EPOXIDE HYDROLASES FROM STREPTOMYCES | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048327-A1 | Aza-peptide epoxides | ANPEP, ENPEP, TMPRSS15 | FASN 2663/4885KEAP1 631/4885FDFT1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.